Economic Recovery: US Contract Biomanufacturing Companies Are Experiencing an Upswing
For the past decade or more, small to mid-sized biotechnology companies had been outsourcing production of their preclinical and clinical protein-based products to Asian contract manufacturing organizations (CMOs). This was because manufacturing and labor costs were lower and product quality was consistent with Western standards and requirements. However, the recent economic down turn coupled with rising prices at Asian CMOs (mainly driven by increasing labor and project management costs) has forced many small to mid-sized companies to rely again on American CMOs to manufacture their products. Unlike cash-rich, larger companies, US small to midsize companies generally lack the financial resources and personnel to effectively manage operations in Asia. Many industry analysts contend that the lower initial costs of Asia-based companies are usually offset by the money and resources need to oversee a project.
While business returning from Asia improved the financial outlook for some American CMOs, 2009 was a bad year for most firms that service small to mid-sized pharma and biotech companies. However, industry analysts expect 2010 to be better than 2009. More importantly, the return of biomanufacturing to the US may signal the beginning of a new trend in the biomanufacturing outsourcing industry.
Until next time....
Good Luck and Good Job Hunting!!!!!!!!!!
.png)
While surfing the web, I came upon a cool website called Foldit. Foldit is an online competitive, interactive protein folding game that showcases the principles and properties of protein biochemistries.
.jpg)
rush of energy simply by getting a whiff of freshly-brewed joe? If you do, there may be a genetic explanation for it.
There are currently two injectable products on the market that are used to treat chronic Hepatitis C infections. Both products, 
